NCI-designated Consortium Cancer Center
|
|
|
Send any questions to:
Nadia Swanson (nadia.swanson@qiagen.com)
Scott Burrows (scott.burrows@qiagen.com)
|
|
|
Accepting Applications for Associate Director,
Diversity, Equity, and Inclusion
|
|
|
|
Moores Cancer Center (MCC) is recruiting an Associate Director of Diversity, Equity, and Inclusion (DEI) to lead DEI initiatives that foster an inclusive and anti-racist environment for all members and employees of the MCC. The position has been established to support the National Cancer Institute’s commitment to ensure that (1) all Americans share equally in the medical advances that result from cancer research and (2) current disparities in the cancer burden are reduced or eliminated. As such, the position will provide strategic leadership, coordination, and implementation of DEI-related programs, initiatives, policies, and evaluative activities to enhance the diversity of MCC staff, faculty, students, and leadership.
For more information on this exciting opportunity, please visit the link below.
DEADLINE: July 31, 2022
MORE INFO
|
|
|
Accepting Applications for Vice Chair, Data and Safety Monitoring Committee (DSMC)
|
|
|
| Compensation
Effort: 5% up to NIH cap
Required Qualifications
Faculty member of UCSD, SDSU, or LJI with experience as a PI of a cancer clinical trial
Moores Cancer Center (MCC) Member
Experience as PI/Site PI of Phase I/II investigator-initiated trials
Preferred Qualifications
An ideal candidate would have experience in both industry sponsored and investigator-initiated cancer therapeutics trials
Detail oriented
Committed to maintaining the integrity of clinical trials at MCC and executing the Data Safety and Monitoring Plan as written in the Cancer Center Support Grant
Time Commitment
2-4 hours per month for Committee meetings plus time to review material prior to meetings; more depending on level of involvement with other projects or potential of ad hoc reviews
Term
Recommended to be 3 years
DEADLINE: July 15, 2022
MORE INFO
|
|
|
Nominate an Emerging Leader in Immunology and Cancer Immunotherapy
|
|
|
|
The Society for Immunotherapy of Cancer (SITC) is pleased to announce the call for nominations for the 2022 Steven A. Rosenberg Scholars Award, one of the society's most prestigious opportunities for early career scientists.
SITC is seeking the best and brightest to continue Dr. Rosenberg’s legacy with a research award for early career scientists who are interested in tackling the challenges that face the field of cancer immunotherapy. Nominations are due July 15, 2022 and will be accepted via email to development@sitcancer.org.
|
|
|
Division of Regenerative Medicine Seminar Series
"Identifying Signatures of Neural Stem Cell State”
Monday, July 18, 2022
3:00 p.m. -4:00 p.m.
Darcie Moore, Ph.D.
Assistant Professor
Department of Neuroscience
University of Wisconsin – Madison
ZOOM MEETING LINK
Hosted by: Rob Signer, Ph.D.
For more information, contact: drmseminarseries@ucsd.edu (858) 822-4258, or mellison@health.ucsd.edu
To encourage open and engaging scientific discussions, please remember all presentations and discussions will be confidential and should not be discussed elsewhere without authorization from the presenters.
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
| Wednesday, July 20, 2022
2:00 p.m. - 3:00 p.m.
Virtual Workshop: "Federal Grant Opportunities in Healthcare"
Moores Cancer Center is partnering with the Office of Congressman Scott Peters to present a panel for those in the community who would like to learn more about how to apply to federal grants.
Speakers include Dr. James Murphy and Dr. Elena Martinez, who will be sharing insights and experiences in this process.
ZOOM MEETING LINK
|
|
|
Thursday, July 23, 2022
9:00 a.m. - 10:00 a.m.
"Keeping Kids Healthy: HPV Vaccinations"
Moores Cancer Center is partnering with Assembly Member Dr. Akilah Weber’s office to present HPV vaccination information to the community.
Speakers
Maya Kumar, M.D., UC San Diego Health
Mike West, J.D., HPV Cancer Survivor and Advocate
Andrew Gonzalez, Champions for Health
Registration link to come!
|
|
|
August 1–5: California HPV Vaccine Week
Look out for events and information on HPV vaccination learning opportunities! Partner Assemblymember Dr. Akilah Weber is introducing a resolution in the state assembly. Be sure to follow us on Twitter @UCSDCancer_COE for updates. More to come!
MORE INFO
|
|
|
Saturday, August 13, 2022
10:00 a.m. - 1:00 p.m.
"Backpack Giveaway and HPV Vaccination Clinic"
Moores Cancer Center is partnering with Assembly Member Dr. Akilah Weber’s office to make HPV vaccinations available via our community partner Champions for Health. Cancer education also will be provided at the event.
Time and location to come!
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITY
|
| |
HHRI Freeman Hrabowski Scholars Program
Awards will cover full salary, benefits, and a research budget of ~$2M direct /5y
This new program will support outstanding basic researchers, including physician-scientists, who have strong potential to become leaders in their fields and to advance diversity, equity, and inclusion.. Eligible research areas include all basic biomedical science disciplines, as well as plant biology, evolutionary biology, biophysics, chemical biology, biomedical engineering, and computational biology. Applicants must have begun a tenure-track faculty position on or after July 1, 2018, or have accepted an offer for a position that will begin no later than July 1, 2023. Up to 30 awards will be made in 2023; future competitions are anticipated every other year. Watch the recording of an information session.
Applications due: September 28, 2022
|
|
|
DOD Breast Cancer Research Program: Transformative Breast Cancer Consortium Award
$25M direct for up to 4 years
The U.S. Department of Defense, Transformative Breast Cancer Consortium Award is designed to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and accelerate progress toward ending breast cancer. Applicants must bring together different perspectives to develop new paradigms that will solve fundamental yet overarching problems in breast cancer.
Pre-Application Deadline: August 8, 2022
MORE INFO
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
CA22-017 Small Business Transition Grant for Early Career Scientists (R42 Clinical Trial Not Allowed)
Award: Total $275,766 for Phase I awards; $1,838,436 for Phase II awards (NCI 2 years each)
To support not only early-career academic scientists interested in transitioning to entrepreneurship, but also the transfer of technology from academic laboratories to small businesses.
Deadline: August 22, 2022
MORE INFO
|
Administrative Supplements to Support Cancer Disparity Collaborative Research
Award: $150,000 direct for 1 year
The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to (1) promote new cancer disparities research among investigators who do not normally conduct it and (2) encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. Cancer disparities research includes, but is not limited to, basic, translational, behavioral, observational, interventional, environmental, and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden, and/or response to treatment in racial/ethnic minorities and/or underserved populations.
Deadline: September 6, 2022
|
MD22-008 Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional)
Award: $500K direct/year for up to 5 years
To support research that seeks to (1) understand the underlying mechanisms and (2) test interventions that address and mitigate the impact of health-related misinformation and disinformation on health disparities and the populations that experience health disparities.
Deadline: November 13, 2022
MORE INFO
|
Early-Stage/Advanced/Sustained Development of Informatics Technologies for Cancer Research and Management (R21/U01/U24 Clinical Trial Optional
Award: $275K unlimited direct costs 2-5 years, depending on mechanism
This component of the NCI's Informatics Technology for Cancer Research (ITCR) Program targets the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum.
Deadline: November 17, 2022
|
|
|
DOD Breast Cancer Research Program (BCRP): Anticipated Funding Opportunities
These U.S. Department of Defense BCRP awards will support innovative, high-impact research, with a mission of ending breast cancer for service members, veterans, and the general public. Funding mechanisms will include Breakthrough Awards, Era of Hope Scholar Awards, and Innovator Awards.
MORE INFO
|
|
|
FOUNDATION FUNDING OPPORTUNITIES
|
|
|
Mark Foundation for Cancer Research: Endeavor Collaborative Research Awards
$3,000,000 for 3 years
The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to (1) generate and integrate data from diverse lines of research and (2) transform those insights into advances for cancer patients that could not be achieved by individual efforts. A description of the teams granted Endeavor Awards in 2022 can be found here.
MORE INFO
|
|
| |
Tuesday, October 11, 2022
UC San Diego, Moores Cancer Center
Delivering Discoveries Annual Scientific Retreat
Location: Scripps Seaside Forum
8610 Kennel Way, La Jolla, CA 92037
|
|
|
Thursday to Friday, October 20-21, 2022
Time: TBD
Sanford Stem Cell Annual Symposium co-hosted by Moores Cancer Center, Hematologic Malignancies Program
Location: Sanford Consortium, Duane J. Roth Auditorium
2880 Torrey Pines Scenic Drive, La Jolla, CA 92037
-
Recent breakthroughs in regenerative medicine
- Stem cell regeneration in several disease areas
- Interactive discussion panels regarding stem cells in space and stem cell clinical trials
Hosted by
Catriona Jamieson, M.D., Ph.D., Deputy Director of Moores Cancer Center, Director of the Sanford Stem Cell Clinical Center, and Chief of the Division of Regenerative Medicine and Alysson Muotri, Ph.D., Co-Director, Stem Cell Program
Keynote Speakers
Derrick Rossi, Ph.D., Co-Founder, Moderna; Elizabeth Blackburn, Ph.D., Professor, UC San Francisco; and Thomas C. Sudhof, M.D., Professor, Stanford University
MORE INFO
|
Tuesday to Saturday, November 8-12, 2022
Join Us in Person at SITC 2022
37th Annual Meeting & Pre-Conference Programs
Location: Boston Convention and Exhibition Center, Boston, MA. Virtual participation also available at the same registration rates.
REGISTER TODAY!
|
Saturday, January 28, 2023
Prostate Cancer Patient Summit
More information to come!
|
|
|
Newly opened clinical trials (June, 2022)
|
|
|
-
Bryant, A. K., Nelson, T. J., McKay, R. R., Kader, A. K., Parsons, J. K., Einck, J. P., Kane, C. J., Sandhu, A. P., Mundt, A. J., Murphy, J. D., & Rose, B. S. (2021). Impact of age on treatment response in men with prostate cancer treated with radiotherapy. BJUI compass, 3(3), 243–250.
-
Meng, Z., Li, F. L., Fang, C., Yeoman, B., Qiu, Y., Wang, Y., Cai, X., Lin, K. C., Yang, D., Luo, M., Fu, V., Ma, X., Diao, Y., Giancotti, F. G., Ren, B., Engler, A. J., & Guan, K. L. (2022). The Hippo pathway mediates Semaphorin signaling. Science advances, 8(21), eabl9806.
- Leas, E. C., Benmarhnia, T., Strong, D. R., & Pierce, J. P. (2022). Use of Menthol Cigarettes, Smoking Frequency, and Nicotine Dependence Among US Youth. JAMA network open, 5(6), e2217144.
-
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., Bazhenova, L., Negrao, M. V., Pennell, N. A., Zhang, J., Anderes, K., Der-Torossian, H., Kheoh, T., Velastegui, K., Yan, X., Christensen, J. G., … Spira, A. I. (2022). Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. The New England journal of medicine, 10.1056/NEJMoa2204619. Advance online publication.
|
|
|
- SRA3, Req #117074
-
RA2, Post Award (candidates hired into this position can work remotely, in-person or hybrid). Req #117071
-
RA3 or RA2, Pre-Award (candidates hired into this position can work remotely, in-person or hybrid). – Req #116028
-
Financial Analyst 1 – Req #116694
- Financial Analyst 2 – Req #117186
|
|
|
If you have newsworthy items to contribute, please contact our Marketing & Communications Manager, Renee Maude at amaude@health.ucsd.edu.
|
|
|
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The 360 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and risk research, MCC researchers address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. MCC was founded in 1978, the same year it received its NCI designation.
|
|
|
Department of Research Administration
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to .
To continue receiving our emails, add us to your address book.
|
|
|
|
